Gilead and Louisiana agree on a "Netflix" model for hepatitis C drugs


AAfter months of planning, the Louisiana Department of Health has selected a new subsidiary of Gilead Sciences (GILD) to provide a hepatitis C drug based on a payment model called Netflix.

The agreement deals with subscription payments. Asegua Therapeutics, Gilead Unit, has agreed to provide the Medicaid State Program and the Department of Corrections with unrestricted access to an authorized generic version of Epclusa Treatment for a fixed fee for a period of five years. according to the Department of Health. A contract should be finalized by June 1st.

Unlock this item by subscribing to STAT Plus and enjoy your first 30 days for free!


Source link